NASDAQ:QGEN
Qiagen N.V. Stock News
$42.98
+0.300 (+0.703%)
At Close: May 03, 2024
QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification
02:18pm, Friday, 25'th Nov 2022
QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
01:33pm, Wednesday, 23'rd Nov 2022
Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.
QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up
12:02pm, Thursday, 10'th Nov 2022
The ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides for QIAGEN (QGEN).
Qiagen N.V. (QGEN) Q3 2022 Earnings Call Transcript
04:38pm, Tuesday, 08'th Nov 2022
Qiagen N.V. (NYSE:QGEN ) Q3 2022 Results Conference Call November 8, 2022 9:00 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - CEO Roland Sackers - CFO Co
QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast
06:54am, Friday, 21'st Oct 2022
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V.
Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely
12:04pm, Tuesday, 11'th Oct 2022
A rumored matchup between Bio-Rad Laboratories and Qiagen is unlikely, an analyst said Tuesday as BIO stock fell for a second straight day. The post Why Bio-Rad Laboratories' Rumored $10 Billion Qiage
Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market
08:56pm, Monday, 10'th Oct 2022
Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.
Bio-Rad Laboratories in Talks to Combine With Qiagen
02:03pm, Monday, 10'th Oct 2022
Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
08:19pm, Thursday, 22'nd Sep 2022
Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.
QIAGEN (QGEN) Assays to Detect Organ Transplant-Related Viruses
01:32pm, Monday, 19'th Sep 2022
QIAGEN's (QGEN) latest additions to the NeuMoDx assay menu will help identify EBV and HHV-6 viruses in immunocompromised patients.
QIAGEN (QGEN) to Develop Companion Diagnostic for Neuron23
01:34pm, Thursday, 15'th Sep 2022
QIAGEN's (QGEN) novel companion diagnostic assay will help identify individuals who might benefit from Neuron23's drug candidate for Parkinson's disease.
QIAGEN's (QGEN) New Syndromic Test to Combat Monkeypox Spread
03:48pm, Friday, 19'th Aug 2022
QIAGEN (QGEN) joins the global fight against monkeypox with the launch of its novel QIAstat-Dx Viral Vesicular Panel RUO.
Qiagen NV (QGEN) CEO Thierry Bernard on Q2 2022 Results - Earnings Call Transcript
12:43am, Friday, 29'th Jul 2022
Qiagen NV (NYSE:QGEN ) Q2 2022 Earnings Conference Call July 28, 2022 9:30 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - CEO Roland Sacker - CFO Confere
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
02:50pm, Thursday, 28'th Jul 2022
QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
05:53pm, Tuesday, 26'th Jul 2022
Qiagen (QGEN) delivered earnings and revenue surprises of 13.33% and 3.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
